Mylan gets DCGI nod for anti-tuberculosis drug Pretomanid for conditional access
Posted by
www.biotecnika.org
The Drug Controller General of India (DCGI) has approved Pretomanid
for conditional access under the National Tuberculosis Elimination
Program (NTEP), Mylan said in a statement. Through the conditional
access approval from DCGI, Mylan will initially make its Pretomanid
available in India through a donation of 400 treatment courses to the
NTEP, it added.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/mylan-gets-dcgi-nod-for-anti-tuberculosis-drug-pretomanid-for-conditional-access/articleshow/77106553.cms
Subscribe to:
Post Comments (Atom)
Post a Comment